Compare · DXCM vs XRAY
DXCM vs XRAY
Side-by-side comparison of DexCom Inc. (DXCM) and DENTSPLY SIRONA Inc. (XRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and XRAY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 14.0x XRAY ($2.00B).
- Over the past year, DXCM is down 14.9% and XRAY is down 38.3% - DXCM leads by 23.4 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 16 for XRAY).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- DENTSPLY SIRONA Inc.
- Price
- $72.84+0.38%
- $10.01+1.42%
- Market cap
- $28.11B
- $2.00B
- 1M return
- +20.73%
- -10.22%
- 1Y return
- -14.94%
- -38.31%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1987
- News (4w)
- 26
- 16
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest XRAY
- Director Lucier Gregory T received a gift of 38,382 shares, was granted 38,382 shares and gifted 38,382 shares (SEC Form 4)
- Director Zurbay Donald was granted 22,822 shares, increasing direct ownership by 332% to 29,693 units (SEC Form 4)
- Director Vergis Janet S. was granted 22,822 shares, increasing direct ownership by 51% to 67,324 units (SEC Form 4)
- Director Varon Leslie F was granted 22,822 shares, increasing direct ownership by 40% to 80,364 units (SEC Form 4)
- Director Mckeon Brian P was granted 28,887 shares (SEC Form 4)
- Director Mazelsky Jonathan Jay was granted 22,822 shares, increasing direct ownership by 79% to 51,669 units (SEC Form 4)
- Director Hosein Clyde was granted 22,822 shares, increasing direct ownership by 55% to 64,075 units (SEC Form 4)
- Director Holden Betsy D was granted 22,822 shares, increasing direct ownership by 42% to 77,442 units (SEC Form 4)
- Director Gladden Brian T was granted 22,822 shares, increasing direct ownership by 79% to 51,864 units (SEC Form 4)
- Director Forbes James D was granted 28,887 shares, increasing direct ownership by 289% to 38,887 units (SEC Form 4)